כניסה 
עקבו אחרינו בפייסבוק סימבאסטאטין - Simvastatin
מתוך ויקירפואה
| סימבאסטאטין - Simvastatin | ||
|---|---|---|
| שמות מסחריים | ®SIMOVIL® ; SIMVASTATIN® ; SIMVAXON | |
| קבוצה פרמקולוגית (ATC) | "HMG COA REDUCTASE INHIBITORS" | |
| שם גנרי | "סימבאסטאטין" (קישור לדף התרופה במאגר משרד הבריאות) |
|
| סל הבריאות | כלול | |
| מסגרת הכללה בסל | תרופה מוגבלת לרישום ע"י רופא מומחה או הגבלה אחרת. | |
התוויות |
Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvastatin-teva is indicated to: Reduce the risk of total mortality by reducing coronary death ; Reduce the risk of non-fatal myocardial infarction ; Reduce the risk for undergoing myocardial revascularization procedures. Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simvastatin-teva is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvastatin-teva therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvastatin-teva is indicated for the treatment of patients with hypertriglyceridemia ( Fredrickson type IV hyperlipidemia). Dysbetalipoproteinemia (Fredrickson type III hyperlipidemia): Simvastatin-teva is also indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia)
| |
| קיים גם בתכשירים | ®INEGY | |